Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
66,577,393
-
Total 13F shares
-
28,660,334
-
Share change
-
-3,594,991
-
Total reported value
-
$90,269,224
-
Put/Call ratio
-
29%
-
Price per share
-
$3.15
-
Number of holders
-
114
-
Value change
-
-$11,262,617
-
Number of buys
-
63
-
Number of sells
-
41
Institutional Holders of Cardiff Oncology, Inc. - Common Stock (CRDF) as of Q2 2025
As of 30 Jun 2025,
Cardiff Oncology, Inc. - Common Stock (CRDF) was held by
114 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
28,660,334 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, BLAIR WILLIAM & CO/IL, Pfizer Inc, Laurion Capital Management LP, GEODE CAPITAL MANAGEMENT, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., ACORN CAPITAL ADVISORS, LLC, MILLENNIUM MANAGEMENT LLC, and STATE STREET CORP.
This page lists
114
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.